Harrow (HROW) Depreciation & Amortization (CF) (2010 - 2026)
Harrow (HROW) recorded quarterly Depreciation & Amortization (CF) of $455000.0 in Q1 2026, down 1.94% quarter-over-quarter from $464000.0 in Q4 2025, and down 2.15% on a YoY basis from $465000.0 in Q1 2025.
Harrow (HROW) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Harrow's Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $455000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 2.15% year-over-year to $455000.0; the TTM figure through Mar 2026 stood at $1.9 million (up 1.17% YoY), while the FY2025 annual figure was $1.9 million, up 3.51% from the prior year.
- Depreciation & Amortization (CF) was $455000.0 for Q1 2026 at Harrow, down from $464000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $497000.0 in Q3 2024 to a low of $247000.0 in Q3 2022.
- Historically, Depreciation & Amortization (CF) has averaged $425117.6 across 5 years, with a median of $435000.0 in 2023.
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) slumped 38.1% in 2022, then soared 63.97% in 2023.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $387000.0 in 2022, then climbed by 12.4% to $435000.0 in 2023, then gained by 7.59% to $468000.0 in 2024, then fell by 0.85% to $464000.0 in 2025, then slipped by 1.94% to $455000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $455000.0 (Q1 2026), $464000.0 (Q4 2025), and $490000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 239.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 119.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 22.60 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 7.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 172.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 19.43 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 21.95 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 22.68 Mn |
| 10 | Harrow | 1.25 Bn | 1.15 Bn | 27.05 Mn | 455,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 455,000.00 |
| Mar 31, 2026 | 455,000.00 |
| Dec 31, 2025 | 464,000.00 |
| Dec 31, 2025 | 464,000.00 |
| Sep 30, 2025 | 490,000.00 |
| Sep 30, 2025 | 490,000.00 |
| Jun 30, 2025 | 496,000.00 |
| Jun 30, 2025 | 496,000.00 |
| Mar 31, 2025 | 465,000.00 |
| Mar 31, 2025 | 465,000.00 |
| Dec 31, 2024 | 468,000.00 |
| Dec 31, 2024 | 468,000.00 |
| Sep 30, 2024 | 497,000.00 |
| Sep 30, 2024 | 497,000.00 |
| Jun 30, 2024 | 453,000.00 |
| Jun 30, 2024 | 453,000.00 |
| Mar 31, 2024 | 432,000.00 |
| Mar 31, 2024 | 432,000.00 |
| Dec 31, 2023 | 435,000.00 |
| Dec 31, 2023 | 435,000.00 |